

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hansen et al. Confirmation No.: 9325

Application No.: 10/602,838 Group Art Unit: 1654

Filed: June 24, 2003 Examiner: Ha, Julie

For: Liquid Composition of Factor VII Polypeptides

**TERMINAL DISCLAIMER UNDER 37 CFR 1.321**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk Health Care AG is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk Health Care AG was recorded on February 23, 2004, Reel 014993, Frame 0053).

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of commonly-owned US Patent No. 6,833,352 is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to US Patent No. 6,833,352, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of US Patent No. 6,833,352, in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found

invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$140.00, to Novo Nordisk, Inc. Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447.

Respectfully submitted,

Date: November 20, 2009

**/Richard W. Bork, Reg. No. 36,459/**  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Inc.  
Customer Number 23650  
(609) 987-5800